ESC-HFA 2026
9 - 12 May 2026
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.